Portage biotech reports confirmatory preclinical results in mesothelioma supporting first-in-human trial of port-7

Dover, del., april 28, 2025 (globe newswire) -- portage biotech inc. (nasdaq: prtg), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for port-7 (tt-4), a selective adenosine a2b receptor inhibitor.

ATON Ratings Summary

ATON Quant Ranking